Journals / Turkish Neurosurgery / 2020 / Cilt: 30 - Sayı: 3

Tranexamic Acid Utilization in Craniosynostosis Surgery

Pages
407–415
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In case of severe intraoperative transfusion necessity, postoperativeTXA utilization might be considered to minimize potential risks by balancing the pros and cons of the drug.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To analyze the impact of Tranexamic acid (TXA) on perioperative hemodynamics in craniosynostosis surgery.MATERIAL and METHODS: Data of thirty-six children (operated between 2014-2017) were categorized into two groups dependingon TXA delivery.
📊
Key Findings & Data:Postoperative outcome involved variables at admission, 2nd, 6th, 12th, 24th hours.
💡
Conclusion & Impact:In case of severe intraoperative transfusion necessity, postoperativeTXA utilization might be considered to minimize potential risks by balancing the pros and cons of the drug.
🔬Design:Research Article
📍Scope:2014-2017 Verileri
⚙️Variables:Domain Parameters

Özet

AIM: To analyze the impact of Tranexamic acid (TXA) on perioperative hemodynamics in craniosynostosis surgery.MATERIAL and METHODS: Data of thirty-six children (operated between 2014-2017) were categorized into two groups dependingon TXA delivery. Patient demographics, preoperative, intraoperative, postoperative data on hemostasis and metabolic outcomeswere recorded. Blood loss from the drains, estimated blood loss (EBV loss), volume of blood transfusions, hemodynamic alerationsand complications were extracted. Postoperative outcome involved variables at admission, 2nd, 6th, 12th, 24th hours. A multiplelogistic regression analysis was also performed.RESULTS: Demographics presented mean age of 8.14 ± 3.53 months, male/female ratio:1.76/1, procedure length 3.98 ± 0.78hours. Intraoperative analysis indicated TXA deliveries manifested fewer blood transfusion volumes (p=0.002) due to lower EBV loss(4.02 ± 1.19 ml/kg vs. 5.97 ± 1.61 ml/kg, p<0.001) with better metabolic outcome.Postoperative outcomes presented all children manifested hematocrit decline after surgey. TXA did not influence postoperativehemodynamic alterations (p=0.090, p=0.112), despite reduced blood loss from the drains and transfusion necessity (p=0.015,p=0.0175). Intraoperative transfusion volumes and EBV loss were associated with postoperative hemodynamics (OR: 3.033, 95% CI:1.286-7.154; p=0.011; OR: 0.280, 95% CI: 0.081-0.972; p=0.045, respectively). ROC analysis indicated 10.13 ml/kg of intraoperativeblood transfusion requirement as the cut off value for hemodynamic instability with 91% sensitivity and 80% specificity. One unitincrease in intraoperative transfused blood volume increased the odds of developing hemodynamic alterations by 3.033 times.CONCLUSION: Intraoperative TXA is crucial for successful surgical management; however postoperative period carries outparamount importance due to excessive bleeding after surgery. In case of severe intraoperative transfusion necessity, postoperativeTXA utilization might be considered to minimize potential risks by balancing the pros and cons of the drug.

🔖

Cite This Article

ONGUN, E. A., DURSUN, O., KAZAN, M. S. (2020). Tranexamic Acid Utilization in Craniosynostosis Surgery. Turkish Neurosurgery, Cilt: 30 - Sayı: 3, 407–415. https://ajindex.com/articles/402973

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Abrishami A, Chung F, Wong J: Topical application of antifibrinolytic drugs for on-pump cardiac surgery: A systematic review and meta-analysis. Can J Anesth 56(3):202- 212, 2009 2. Carver E, Marcus R, Tatman AF: FFP use in craniofacial surgery. Paediatr Anaesth 20(5):471, 2010 3. Chung E, Karlberg HI: Ulnar artery thrombosis following tranexamic acid administration for craniosynostosis repair. J Craniofac Surg 30(1):186-187, 2019 4. Crantford JC, Wood BC, Claiborne JR, Ririe DG, Couture DE, Thompson JT, David LR: Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. J Craniofac Surg 26(1):104–107, 2015 5. Czerwinski M, Hopper RA, Gruss J, Fearon JA: Major morbidity and mortality rates in craniofacial surgery: An analysis of 8101 major procedures. Plast Reconstr Surg 126(1):181-186, 2010 6. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J: Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97(2):390-399, 2002 7. Durán de la Fuente P, García Fernández J, Pérez López C, Carceller F, Gilsanz Rodríguez F: Usefulness of tranexamic acid in cranial remodeling surgery. Rev Esp Anestesiol Reanim 50(8):388-394, 2003 8. Goobie SM, Cladis FP, Glover CD, Huang H, Reddy SK, Fernandez AM, Zurakowski D, Stricker PA, Gries H; The Pediatric Craniofacial Collaborative Group: Safety of antifibrinolytics in cranial vault reconstructive surgery: A report from the pediatric craniofacial collaborative group. Paediatr Anaesth 27(3):271-281, 2017 9. Goobie SM, Meier PM, Pereira LM, McGowan FX, Prescilla RP, Scharp LA, Rogers GF, Proctor MR, Meara JG, Soriano SG, Zurakowski D, Sethna NF: Efficacy of tranexamic acid in pediatric craniosynostosis surgery: A double-blind, placebocontrolled trial. Anesthesiology 114(4):862-871, 2011 10. Goobie SM, Meier PM, Sethna NF, Soriano SG, Zurakowski D, Samant S, Pereira LM: Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery. Clin Pharmacokinet 52(4):267-276, 2013 11. Goobie SM, Zurakowski D, Proctor MR, Meara JG, Meier PM, Young VJ, Rogers GF: Predictors of clinically significant postoperative events after open craniosynostosis surgery. Anesthesiology 122(5):1021–1032, 2015 12. Hans P, Collin V, Bonhomme V, Damas F, Born JD, Lamy M: Evaluation of acute normovolemic hemodilution for surgical repair of craniosynostosis. J Neurosurg Anesthesiol 12(1):33- 36, 2000 13. Hansen JK, Lyd